The OVACell Project
Ovarian cancer is one of the most ruthless diseases affecting women today. It spreads quietly, evades early detection, and by the time most patients receive a diagnosis, treatment options are already limited. But a small European biotech company called ErVimmune is working on a novel approach that could change the odds — by turning the immune system into a precision weapon using targets hidden inside our own DNA.
The OVACell project, led by ErVimmune and backed by the European Innovation Council, is pioneering T cell therapies that target a highly unconventional class of antigens: human endogenous retroviruses, or HERVs. These are ancient viral sequences that have been dormant in human DNA for millennia — but in tumour cells, they wake up. OVACell exploits this abnormal activity, training the immune system to recognize and destroy cells expressing these reactivated sequences, while leaving healthy tissue untouched.
What makes this approach particularly compelling is its precision. The team uses a proprietary methodology combining AI-driven data analysis, immunopeptidomics, and in vitro testing to ensure the highest levels of specificity and safety. Rather than broad-spectrum treatments that harm healthy cells alongside cancerous ones, OVACell is working toward therapies that are as targeted as they are powerful.
The project first developed a vaccine for both triple-negative breast cancer and ovarian cancer, targeting sequences shared across a wide patient population spanning Europe, North America, and the ASEAN region. Building on that success, the team is now advancing a dedicated T cell therapy specifically for ovarian cancer — a disease with very high unmet medical need, where relapse is common and late diagnosis dramatically reduces survival rates.
Despite being a small team, ErVimmune has made remarkable strides through strategic collaboration. They work with contract manufacturers in France to scale production, alongside regulatory and clinical partners to navigate complex safety and efficacy requirements. It’s a reminder that in cutting-edge medical research, the network around a team can be just as important as the team itself.
At the heart of this work is a deeply human motivation. As CEO Nathalie Donne puts it, the team is guided by the reality patients face — not just the science. With EIC support, OVACell is now preparing for preclinical evaluation, with the goal of demonstrating safety and efficacy in humans in the coming years.
In a field that so desperately needs new answers, OVACell is proof that big breakthroughs can come from small, focused teams with the courage to look somewhere no one else thought to look — in this case, billions of years back in our own genetic history.
This topic was featured in Great News podcast episode 36.
The Great News Podcast is your source for positive news, inspiring stories, and good news from around the world. We skip the doom and gloom of mainstream media to focus on scientific breakthroughs, environmental wins, and the inspiring news that proves the world is getting better. Join Andrew McGivern for a dose of optimism and uplifting stories that will change your perspective on human progress.
It is easy to find the
Keep looking for the good in the world, because it is not only there – its everywhere.
This episode is brought to you by the Daily Quote. The podcast designed to kickstart your day in a positive way.
Today, we are diving into some truly groundbreaking advancements in medicine, biotechnology, and sustainable energy. What if a gene editor could replicate and spread like a virus to ensure it reaches every cell that needs a cure? That is our lead story today.
Plus, we have a ”rechargeable sun battery” that outperforms lithium-ion, tiny bubbles that shatter cancer’s defenses, and a city-wide success story in wiping out Dengue fever.
CRISPR Gene Editor Replicates and Spreads Like a Virus
New Sun Battery Beats Lithium-Ion
Bubbles and Ultrasound Break Soften Tumour Walls for Better Treatment
And don’t forget to stick around for the speed round, where we’ll dive into even more great news.Prime C Shows Striking Survival Benefit in ALS Clinical Trial
Inhalable Treatment Could Replace Months of Pills for TB
Could a “Longevity Protein” Slow How We Age?An Inflammation Suppressor Decreases Mortality
Turning Our Own DNA Against Cancer
Until next time, keep looking for the good in the world, because it’s not only there—it’s everywhere.
Source: News Medical Life Sciences
